Tenderwize
Retour à la recherche

Open House Original Discount Contracts 2025-27 - Ribociclib

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 430 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-27 - Ribociclib

70/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

70 / 100

Complexité

20 / 100

Facteurs de risque

Contract ends automatically at the end of the month in which the patent or market exclusivity for Ribociclib expires. T...

No estimated value or volume is provided; revenue is uncertain and depends on actual prescriptions.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclude discount contracts for the active ingredient Ribociclib with eligible pharmaceutical entrepreneurs.
  • Ensure pharmacy software update for new discount products by submitting documents before the 3rd of the preceding month.
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse (TK) to conclude discount contracts (Rabattverträge) for the active ingredient Ribociclib under §130c SGB V. The process is non-competitive: any eligible pharmaceutical entrepreneur that meets the criteria (valid marketing authorization, being a pharmaceutical entrepreneur within EU/EEA) can join at any time during the contract duration (01.11.2025 – 31.10.2027). No exclusivity is granted. The notice clarifies this is not a public procurement under EU directives; legal recourse is to social courts. No estimated value is provided. Contract termination occurs automatically upon patent expiry. Documents are available online but submission is via email or post (not electronic via the platform).

Risques

Contract ends automatically at the end of the month in which the patent or market exclusivity for Ribociclib expires. T...

No estimated value or volume is provided; revenue is uncertain and depends on actual prescriptions.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Be a pharmaceutical entrepreneur within the meaning of §4(18) AMG, with a valid marketing authorization (or equivalent right) for Ribociclib.

Eligibility

  • No exclusion grounds analogous to §§123, 124 GWB for the last 3-5 years.

Administrative

  • Submit signed contract documents (including self-declaration on authorization and company – Anlage 4) via email with qualified electronic signature or by post.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Original Discount Contracts 2025-27 - Ribociclib

Conclusion of discount contracts for the active ingredient Ribociclib with eligible pharmaceutical entrepreneurs. The contract has a maximum duration of 24 months starting 01.11.2025, ending no later than 31.10.2027. Early termination upon patent expiry.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Oct 2025 - Oct 2027

Catégorie

Pharmaceutical products

Détails de la procédure

Date de publication
17 Sep 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
612458-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3